1. A pharmaceutical composition comprising an active ingredient selected from risperidone, a salt thereof, 9-hydroxyrisperidone and a salt thereof； and a polymer mixture comprising a first non-terminated polylactide glycolide and a second non-terminated polylactide glycolide, wherein the weight content of the active component in the pharmaceutical composition is in the range from 10 to 60%, preferably from 35 to 55%, more preferably from 40 to 50%； the weight content of the polymer mixture in the pharmaceutical composition is in the range from 40 to 90%, preferably from 45 to 65%, more preferably from 50 to 60%； and the pharmaceutical composition is in the form of microspheres. 2. The pharmaceutical composition according to claim 1, wherein the polymer mixture consists of a first non-terminated polylactide glycolide and a second non-terminated polyl actide glycolide. The pharmaceutical composition of claim 1 or 2, wherein the first non-terminated polylactide glycolide has high intrinsic viscosity, 0.4-0.9 dl / g, preferably 0.45-0.8 dl / g, more preferably 0.45-0.55 dl / g, and the second non-terminated polylactide glycolide has a low intrinsic viscosity, 0.1-0.35 dl / g, preferably 0.1-0.3 dl / g, more preferably 0.2-0.3 dl / g. 4. The pharmaceutical composition of claim 3, wherein the weight ratio of the first non-terminated polylactide glycolide to the second non-terminated polylactide glycolide is (50-95) :( 5-50), preferably (70-90) :( 10-30), more preferably 80: 20.5. The pharmaceutical composition according to claim 3, wherein the lactide-glycolide molar ratio in the first non-terminated polylactide-glycolide is in the range of 65:35 to 90:10, preferably 75:25； and molar ratio of lactide to glycolide in the second nonterm1. Фармацевтический состав, включающий активный компонент, выбранный из рисперидона, его соли, 9-гидроксирисперидона и его соли； и полимерную смесь, включающую первый нетерминированный полилактид-гликолид и второй нетерминированный полилактид
